Compare NextEra Energy, Inc. (NEE) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NextEra Energy, Inc. vs Novavax Inc — how do they compare? NextEra Energy, Inc. trades at $76.97 (market cap $161.39B), while Novavax Inc trades at $11.09 (market cap $1.82B). The key difference: NextEra Energy, Inc. is far larger — about 88.7× Novavax Inc's market cap, and NextEra Energy, Inc. pays a 3.22% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold NextEra Energy, Inc. for 83 Days and Novavax Inc for 59 Days on average.
| NEE | NVAX | |
|---|---|---|
Market Cap | $161.39B | $1.82B |
Volume | 11,780,955 | 6,198,505 |
Sector | Utilities | Health |
52-Week High | $97.88 | $12.56 |
52-Week Low | $75.49 | $6.22 |
Typical Hold Time | 83 Days | 59 Days |
Enterprise Value | $268.72B | $1.39B |
Dividend Yield | 3.22% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NextEra Energy (NEE) trades at $77.06, down 1.05% today, near its 52-week low of $74.78. The stock shows mixed signals with a bearish technical outlook but strong fundamentals, including a 32.4% net income margin and recent earnings beats. Recent news highlights growth initiatives like the Project Star energy infrastructure partnership and a dividend of $0.62 payable in September 2026.
NEE offers a compelling valuation with a P/E of 17.39 and a consensus price target of $96, implying 25% upside. Risks include high debt levels and interest rate sensitivity, but analyst sentiment remains bullish with 66.7% buy ratings. The stock is positioned for long-term growth in clean energy, though near-term volatility may persist.
Novavax (NVAX) trades at $11.22, down 0.88% on the day, with a bullish technical signal from moving averages and a neutral RSI. The company reported strong revenue of $1.12 billion in 2025 and a net income of $440.30 million, but faces negative cash flow and a projected net loss for 2026. Recent news highlights its strategic pivot to a partnership-driven model using its Matrix-M adjuvant technology, with regulatory approvals for its updated COVID-19 vaccine in key markets.
The outlook for NVAX is mixed, with analyst consensus strongly favoring a buy rating (73.92%) but significant financial risks including negative equity, persistent cash burn, and volatile earnings. Investment opportunity lies in the successful execution of its licensing strategy and expansion into oncology, though execution risks and competitive pressures remain key concerns for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NextEra Energy, Inc.
NextEra Energy's regulated utility, Florida Power & Light, distributes power to more than 5 million customers in Florida. FP&L contributes more than 60% of the group's operating earnings. The renewable energy segment generates and sells power throughout the United States and Canada. Consolidated generation capacity totals more than 50 gigawatts and includes natural gas, nuclear, wind, and solar assets.
Read more on NEE →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
